Advertisement

Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study

  • Nobuhiro Fujiyama
  • Shigeru SatohEmail author
  • Mitsuru Saito
  • Kazuyuki Numakura
  • Takamitsu Inoue
  • Ryuhei Yamamoto
  • Takuro Saito
  • Sohei Kanda
  • Shintaro Narita
  • Yoko Mitobe
  • Tomonori Habuchi
Original article
  • 19 Downloads

Abstract

Background

We evaluated the impact of persistent preformed donor-specific antibody (DSA) and de novo DSA (dnDSA) detected at 1 year posttransplantation on long-term death-censored graft survival.

Methods

One hundred and sixty adult patients who received living kidney allograft with pretransplant-negative T-cell complement-dependent cytotoxicity crossmatch (CDCXM), and without periodic screening for DSA, were eligible for this study. All enrolled patients were retrospectively tested for DSA using the Luminex assay. The presence of DSA was analyzed in stored serum samples collected at 1 year posttransplantation. If the recipients had DSA, it was analyzed in the pretransplant serum sample. The detection of DSA solely in the 1 year posttransplant sample was defined as dnDSA, and DSA detection in both pretransplant and 1 year posttransplant samples was defined as persistent preformed DSA.

Results

DSAs were identified in 14 (8.8%) of the 160 patients. Seven patients had persistent preformed DSA, 6 had dnDSA, and 1 had both persistent preformed and dnDSA at 1 year posttransplantation. Death-censored allograft survival rates of patients with DSA versus those without DSA at 7 and 11 years were 77.9 vs. 97.8% and 60.6 vs. 89.2%, respectively. The graft survival rate was lower in patients with persistent preformed DSA and/or dnDSA. Each case of preformed DSA and dnDSA was associated with long-term graft survival.

Conclusion

The presence of persistent preformed DSA or dnDSA at 1 year posttransplantation may be a predictor of long-term graft survival. Further study is needed to evaluate whether periodic screening for DSA improves long-term graft survival.

Keywords

Persistent preformed DSA De novo DSA Long-term graft survival Luminex assay MFI C1q-binding DSA 

Notes

Acknowledgments

This work was partly supported by Grants (Nos.15K18915 and 17K16773) from the Japan Society for the Promotion of Science, Tokyo, Japan.

Funding

This work was partly supported by Grants (15K18915, and 17K16773) from the Japan Society for the Promotion of Science, Tokyo, Japan.

Compliance with ethical standards

Conflicts of interest

The authors declare no conflicts of interest.

Ethical approval

We obtained appropriate Institutional Review Board approval (IRB approval number: 2147).

References

  1. 1.
    Lefaucheur C, Loupy A, Hill GS, Adrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney. Transplant J Am Soc Nephrol. 2010;21:1398–406.CrossRefGoogle Scholar
  2. 2.
    Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–67.CrossRefGoogle Scholar
  3. 3.
    Dunn TB, Noreen H, Gillingham K, Maurer D, Goruroglu Ozturk O, Pruett TL, et al. Revisiting tranditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant. 2011;11:2132–43.CrossRefGoogle Scholar
  4. 4.
    Lobashevsky A, Goggins W, Rosner K, Taber T. Immunogenicity of Class I HLA but not preformed low MFI donor specific antibodies correlates with outcomes after first renal transplantation. Transpl Immunol. 2017;43–44:42–8.CrossRefGoogle Scholar
  5. 5.
    Adebiyi OO, Gralla J, Klem P, Freed B, Davis S, Wiseman AC, et al. Clinical significance of pretransplant donor-specific antibodies in the setting of negative cell-based flow cytometry crossmatching in kidney transplant recipients. Am J Transplant. 2016;16:3458–67.CrossRefGoogle Scholar
  6. 6.
    Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen beads. Transplantation. 2009;87:1681–8.CrossRefGoogle Scholar
  7. 7.
    Kiberd BA, Miller A, Martin S, Tennankore KK. De novo donor-specific human leukocyte antigen antibody screening in kidney transplant recipients after the first year posttransplantation: a medical decision analysis. Am J Transplant. 2016;16:3212–9.CrossRefGoogle Scholar
  8. 8.
    Morath M, Opelz G, Zeier M, Susal C. Clinical relevance of HLA antibody monitoring after kidney transplantation. J Immunol Res. 2014.  https://doi.org/10.1155/2014/845040.Google Scholar
  9. 9.
    Aubert O, Loupy A, Hidalgo L, van Huyen JD, Higgins S, Viglietti D, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017;28:1912–23.CrossRefGoogle Scholar
  10. 10.
    Amrouche L, Aubert O, Suberbielle C, Rabant M, van Huyen JD, Martienz F, et al. Long-term outcomes of kidney transplantation in patients with high levels of preformed DSA: the necker high-risk transplant program. Transplantation. 2017;101:2440–8.CrossRefGoogle Scholar
  11. 11.
    de Sousa MV, Goncalez AC, Zollner RL, Mazzali M. Effect of preformed or de novo anti-HLA antibodies on function and graft survival in kidney transplant recipients. Ann Transplant. 2018;23:457–66.CrossRefGoogle Scholar
  12. 12.
    Riethmuller S, Ferrari-Lacraz S, Muller MK, Raptis DA, Hadaya K, Rusi B, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation. 2010;90:160–7.CrossRefGoogle Scholar
  13. 13.
    Kwon H, Kim YH, Choi JY, Shin S, Jung JH, Park SK, et al. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches. Clin Transplant. 2018;32:e13266.CrossRefGoogle Scholar
  14. 14.
    Zecher D, Bach C, Preiss A, Staudner C, Utpatel K, Evert M, et al. Analysis of luminex-based algorithms to define unacceptable HLA antibodies in CDC-crossmatch negative kidney transplant recipients. Transplantation. 2018;102:969–77.CrossRefGoogle Scholar
  15. 15.
    Loupy A, Lefaucheur C, Vernerey D, Prugger C, van Huyen JD, Mooney N, et al. Complement-biding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369:1215–26.CrossRefGoogle Scholar
  16. 16.
    Wiebe C, Gareau AJ, Pochinco DP, Gibson IW, Ho J, Birk PE, et al. Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival. Am J Transplant. 2017;17:703–11.CrossRefGoogle Scholar
  17. 17.
    Moktefi A, Parisot J, Desvaux D, Canoui-Poitrine F, Brocheriou I, Peltier J, et al. C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study. Transpl Int. 2016;30:277–87.CrossRefGoogle Scholar
  18. 18.
    Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–23.CrossRefGoogle Scholar
  19. 19.
    Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753–60.CrossRefGoogle Scholar
  20. 20.
    Malheiro J, Tafulo S, Dias L, Martins LS, Fonseca I, Beirao I, et al. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation. Transpl Immunol. 2015;32:66–71.CrossRefGoogle Scholar
  21. 21.
    Heilman RL, Nijim A, Desmarteau YM, Khamash H, Pando MJ, Smith ML, et al. De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation. Transplantation. 2014;98:1310–5.CrossRefGoogle Scholar
  22. 22.
    Caillard S, Becmeur C, Gautier-Vargas G, Olagne J, Muller C, Cognard N, et al. Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation. Transplant Int. 2017;30:29–40.CrossRefGoogle Scholar
  23. 23.
    Kauke T, Oberhauser C, Lin V, Coenen M, Fischereder M, Dick A, et al. De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-biding ability. Transplant Int. 2017;30:360–70.CrossRefGoogle Scholar
  24. 24.
    Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, et al. Pretransplant C3d-fixing donor-specific anti-HLA antibodies are not associated with increased risk for kidney graft failure. J Am Soc Nephrol. 2018;29:2279–85.CrossRefGoogle Scholar
  25. 25.
    Ramon D, Huang Y, Zhao L, Rendulic T, Park JM, Sung RS, et al. Use of complement biding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation. Hum Imunol. 2017;78:57–63.CrossRefGoogle Scholar
  26. 26.
    Bailly E, Anglicheau D, Blancho G, Gatault P, Vuiblet V, Chatelet V, et al. Prognostic value of the persistence of C1q-biding anti-HLA antibodies in acute antibody-mediated rejection in kidney transplantation. Transplantation. 2018;102:688–98.CrossRefGoogle Scholar
  27. 27.
    Ponsirenas RVG, Cazarote HB, Araujo SA, Wanderley DC, Shmakura S, Valdameri JS, et al. Anti-HLA donor-specific IgG subclasses and C1q-biding evolution in posttransplant monitoring. Transplant Direct. 2018;4:e385.CrossRefGoogle Scholar
  28. 28.
    Lan JH, Gjertson D, Zheng Y, Clark S, Reed EF, Cecka MJ. Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction. Am J Transplant. 2018.  https://doi.org/10.1111/ajt.14871.Google Scholar
  29. 29.
    Buttigieg J, Ali H, Sharma A, Halawa A. Positive Luminex and negative flow cytometry in kidney transplantation: a systematic review and mata-analysis. Nephrol Dial Transplant 2018.  https://doi.org/10.1093/ndt/gfy349.Google Scholar
  30. 30.
    Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, et al. Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J Am Soc Nephrol. 2017;28:702–15.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  • Nobuhiro Fujiyama
    • 1
  • Shigeru Satoh
    • 1
    Email author
  • Mitsuru Saito
    • 2
  • Kazuyuki Numakura
    • 2
  • Takamitsu Inoue
    • 2
  • Ryuhei Yamamoto
    • 2
  • Takuro Saito
    • 2
  • Sohei Kanda
    • 2
  • Shintaro Narita
    • 2
  • Yoko Mitobe
    • 1
  • Tomonori Habuchi
    • 2
  1. 1.Center for Kidney Disease and TransplantationAkita University HospitalAkitaJapan
  2. 2.Department of UrologyAkita University School of MedicineAkitaJapan

Personalised recommendations